Rigel Pharmaceuticals (RIGL) Other financing activities (2014 - 2026)
Rigel Pharmaceuticals (RIGL) posted quarterly Other financing activities of $321000.0 for Q1 2026, down 33.68% year-over-year from $484000.0 in Q1 2025, and down 89.04% quarter-over-quarter from $2.9 million in Q4 2025.
Rigel Pharmaceuticals (RIGL) Other financing activities (2014 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Other financing activities history runs 13 years deep, the most recent figure standing at $321000.0 for Q1 2026.
- In Q1 2026, Other financing activities fell 33.68% year-over-year to $321000.0; the TTM figure through Mar 2026 stood at $7.9 million (up 236.5% YoY), while the FY2025 annual figure was $8.1 million, up 312.47% from the prior year.
- Other financing activities for Q1 2026 stood at $321000.0, down from $2.9 million in the prior quarter.
- The five-year high for Other financing activities was $4.3 million in Q3 2025, with the low at $1000.0 in Q1 2023.
- The 5-year median for Other financing activities is $485000.0 (2023), against an average of $847437.5.
- The sharpest annual moves came in 2023 and 2024: Other financing activities slumped 99.89% in 2023, then soared 8800.0% in 2024.
- Rigel Pharmaceuticals' Other financing activities stood at $585000.0 in 2022, then retreated by 16.92% to $486000.0 in 2023, then jumped by 201.44% to $1.5 million in 2024, then surged by 99.86% to $2.9 million in 2025, then slumped by 89.04% to $321000.0 in 2026.
- Business Quant data shows RIGL's Other financing activities at $321000.0 in Q1 2026, $2.9 million in Q4 2025, and $4.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Rigel Pharmaceuticals | 795.39 Mn | 700.06 Mn | 70.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.86 Mn |
| Jun 30, 2026 | 1.86 Mn |
| Mar 31, 2026 | 321,000.00 |
| Mar 31, 2026 | 321,000.00 |
| Dec 31, 2025 | 2.93 Mn |
| Dec 31, 2025 | 2.93 Mn |
| Sep 30, 2025 | 4.27 Mn |
| Sep 30, 2025 | 4.27 Mn |
| Jun 30, 2025 | 418,000.00 |
| Jun 30, 2025 | 418,000.00 |
| Mar 31, 2025 | 484,000.00 |
| Mar 31, 2025 | 484,000.00 |
| Dec 31, 2024 | 1.47 Mn |
| Dec 31, 2024 | 1.47 Mn |
| Sep 30, 2024 | 158,000.00 |
| Sep 30, 2024 | 158,000.00 |
| Jun 30, 2024 | 252,000.00 |
| Jun 30, 2024 | 252,000.00 |
| Mar 31, 2024 | 89,000.00 |
| Mar 31, 2024 | 89,000.00 |